{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:52Z","timestamp":1791828592251,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02627-8","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:03:23Z","timestamp":1769583803000},"page":"629-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of SGLT-2 inhibitors in patients with glycogen storage disease type Ib and their efficacy in treating disease-associated digestive symptoms and disorders"],"prefix":"10.1007","volume":"63","author":[{"given":"Ziqiu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6616-2959","authenticated-orcid":false,"given":"Huaien","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"1","key":"2627_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41572-023-00456-z","volume":"9","author":"WB Hannah","year":"2023","unstructured":"Hannah WB, Derks TGJ, Drumm ML, Gr\u00fcnert SC, Kishnani PS, Vissing J (2023) Glycogen storage diseases. Nat Rev Dis Prim 9(1):46. https:\/\/doi.org\/10.1038\/s41572-023-00456-z","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"2627_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.paed.2022.12.007","volume":"33","author":"M Yeo","year":"2023","unstructured":"Yeo M, Moawad H, Grunewald S (2023) Disorders of carbohydrate metabolism: a review of glycogen storage disorders. Paediatr Child Health 33(3):65\u201372. https:\/\/doi.org\/10.1016\/j.paed.2022.12.007","journal-title":"Paediatr Child Health"},{"issue":"1","key":"2627_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-025-03570-1","volume":"20","author":"X Zhang","year":"2025","unstructured":"Zhang X, Su Z, Wu J, Zeng H, Jiang X, Wang Y et al (2025) Gastrointestinal complications of hepatic glycogen storage disease: a national survey questionnaire study in China. Orphanet J Rare Dis 20(1):41. https:\/\/doi.org\/10.1186\/s13023-025-03570-1","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"2627_CR4","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1007\/s00431-002-1011-z","volume":"161","author":"BK Dieckgraefe","year":"2002","unstructured":"Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L (2002) Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 161(Suppl 1):S88-92. https:\/\/doi.org\/10.1007\/s00431-002-1011-z","journal-title":"Eur J Pediatr"},{"issue":"25","key":"2627_CR5","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.3748\/wjg.v29.i25.3932","volume":"29","author":"E G\u00fcm\u00fc\u015f","year":"2023","unstructured":"G\u00fcm\u00fc\u015f E, \u00d6zen H (2023) Glycogen storage diseases: an update. World J Gastroenterol 29(25):3932\u20133963. https:\/\/doi.org\/10.3748\/wjg.v29.i25.3932","journal-title":"World J Gastroenterol"},{"issue":"11","key":"2627_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1038\/gim.2014.128","volume":"16","author":"PS Kishnani","year":"2014","unstructured":"Kishnani PS, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A et al (2014) Diagnosis and management of glycogen storage disease type I: a practice guideline of the American college of medical genetics and genomics. Genet Med 16(11):e1\u2013e29. https:\/\/doi.org\/10.1038\/gim.2014.128","journal-title":"Genet Med"},{"issue":"4","key":"2627_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.1816143116","volume":"116","author":"MA-O Veiga-da-Cunha","year":"2019","unstructured":"Veiga-da-Cunha MA-O, Chevalier N, Stephenne X, Defour JP, Paczia N, Ferster A et al (2019) Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proc Natl Acad Sci U S A 116(4):1241\u20131250. https:\/\/doi.org\/10.1073\/pnas.1816143116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2627_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101803","author":"M Veiga-da-Cunha","year":"2023","unstructured":"Veiga-da-Cunha M, Wortmann SB, Gr\u00fcnert SC, Van Schaftingen E (2023) Treatment of the neutropenia associated with GSD1b and G6PC3 deficiency with SGLT2 inhibitors. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics13101803","journal-title":"Diagnostics"},{"issue":"3","key":"2627_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/jmd2.12278","volume":"63","author":"M Kaczor","year":"2022","unstructured":"Kaczor M, Greczan M, Kierus K, Ehmke Vel Emczy\u0144ska-Seliga E, Ciara E, Pi\u0105tosa B et al (2022) Sodium-glucose cotransporter type 2 channel inhibitor: breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b? JIMD Rep 63(3):199\u2013206. https:\/\/doi.org\/10.1002\/jmd2.12278","journal-title":"JIMD Rep"},{"issue":"9","key":"2627_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"issue":"5","key":"2627_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/jimd.12383","volume":"44","author":"F Peeks","year":"2021","unstructured":"Peeks F, Hoogeveen IJ, Feldbrugge RL, Burghard R, de Boer F, Fokkert-Wilts MJ et al (2021) A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: recommended outcome parameters for glucose management. J Inherit Metab Dis 44(5):1136\u20131150. https:\/\/doi.org\/10.1002\/jimd.12383","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"2627_CR12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.gim.2022.04.001","volume":"24","author":"SC Gr\u00fcnert","year":"2022","unstructured":"Gr\u00fcnert SC, Derks TGJ, Adrian K, Al-Thihli K, Ballhausen D, Bidiuk J et al (2022) Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire. Genet Med 24(8):1781\u20131788. https:\/\/doi.org\/10.1016\/j.gim.2022.04.001","journal-title":"Genet Med"},{"issue":"1","key":"2627_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","volume":"17","author":"RK Halligan","year":"2022","unstructured":"Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR (2022) Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre. Orphanet J Rare Dis 17(1):195. https:\/\/doi.org\/10.1186\/s13023-022-02345-2","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2627_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5114\/pedm.2022.116115","volume":"28","author":"M Kaczor","year":"2022","unstructured":"Kaczor M, Wes\u00f3\u0142-Kucharska D, Greczan M, Kierus K, Ka\u0142u\u017cny \u0141, Du\u015b-\u017buchowska M et al (2022) Clinical characteristics and long-term outcomes of patients with glycogen storage disease type 1b: a retrospective multi-center experience in Poland. Pediatr Endocrinol Diabetes Metab 28(3):207\u2013212. https:\/\/doi.org\/10.5114\/pedm.2022.116115","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"issue":"3","key":"2627_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jmd2.12364","volume":"64","author":"SC Gr\u00fcnert","year":"2023","unstructured":"Gr\u00fcnert SC, Venema A, LaFreniere J, Schneider B, Contreras E, Wortmann SB et al (2023) Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study. JIMD Rep 64(3):252\u2013258. https:\/\/doi.org\/10.1002\/jmd2.12364","journal-title":"JIMD Rep"},{"issue":"11","key":"2627_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1515\/jpem-2023-0336","volume":"36","author":"A K\u00fc\u00e7\u00fck\u00e7ongar Yava\u015f","year":"2023","unstructured":"K\u00fc\u00e7\u00fck\u00e7ongar Yava\u015f A, Engin Erdal A, Bilginer G\u00fcrb\u00fcz B, \u00dcnl\u00fcsoy Aksu A, Kasapkara \u00c7S (2023) Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation. J Pediatr Endocrinol Metab 36(11):1092\u20131099. https:\/\/doi.org\/10.1515\/jpem-2023-0336","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2627_CR17","doi-asserted-by":"publisher","unstructured":"Xia Y, Ge WS, Du TZ, Gong ZZ, Xiao B, Liang LL et al (2023) Therapeutic efficacy of an SGLT 2 inhibitor in five pediatric patients with glycogen storage disease type Ib and inflammatory bowel disease. J Clin Pediatr  41(4):294\u2013299. https:\/\/doi.org\/10.12372\/jcp.2023.22e0095","DOI":"10.12372\/jcp.2023.22e0095"},{"issue":"2","key":"2627_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108486","volume":"142","author":"SC Gr\u00fcnert","year":"2024","unstructured":"Gr\u00fcnert SC, Gautschi M, Baker J, Boyer M, Burlina A, Casswall T et al (2024) Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b. Mol Genet Metab 142(2):108486. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108486","journal-title":"Mol Genet Metab"},{"key":"2627_CR19","doi-asserted-by":"publisher","unstructured":"Jiang JJ, Ma MS, Wei M, Qiu ZQ (2024) Investigation on the treatment of empagliflozin in glycogen storage disease type Ib. Chin J Pediatr 62(6):526\u2013529. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20240301-00136","DOI":"10.3760\/cma.j.cn112140-20240301-00136"},{"issue":"7","key":"2627_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14839","volume":"28","author":"V Rajasekaran","year":"2024","unstructured":"Rajasekaran V, Santra S, Kelgeri C, Johansen L, Vijay S, Sreekantam S et al (2024) Outcomes of pediatric liver transplantation in glycogen storage disease type 1b-a single-center experience. Pediatr Transplant 28(7):e14839. https:\/\/doi.org\/10.1111\/petr.14839","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2627_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13023-024-03137-6","volume":"19","author":"YX Shao","year":"2024","unstructured":"Shao YX, Liang CL, Su YY, Lin YT, Lu ZK, Lin RZ et al (2024) Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study. Orphanet J Rare Dis 19(1):155. https:\/\/doi.org\/10.1186\/s13023-024-03137-6","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2627_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1515\/jpem-2024-0556","volume":"38","author":"E K\u00f6se","year":"2025","unstructured":"K\u00f6se E, \u00d6z\u00e7ay F, Ayd\u0131n H, Kasapkara \u00c7S, \u0130nci A, K\u00fc\u00e7\u00fckcongar Yava\u015f A et al (2025) Effect of empagliflozin treatment on laboratory and clinical findings of patients with glycogen storage disease type Ib: first study from T\u00fcrkiye. J Pediatr Endocrinol Metab 38(4):391\u2013398. https:\/\/doi.org\/10.1515\/jpem-2024-0556","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2627_CR23","doi-asserted-by":"publisher","unstructured":"Jiang JJ, Zheng X, Ma MS, Cui XG, Jian S, Tang XY et al (2023) Short-term efficacy of empagliflozin in children with glycogen storage disease type Ib. Chin J Pediatr 61(6):515\u2013519. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20230131-00067","DOI":"10.3760\/cma.j.cn112140-20230131-00067"},{"issue":"11","key":"2627_CR24","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1182\/bloodadvances.2023012403","volume":"8","author":"M Kaczor","year":"2024","unstructured":"Kaczor M, Malicki S, Folkert J, Dobosz E, Bryzek D, Chruscicka-Smaga B et al (2024) Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin. Blood Adv 8(11):2790\u20132802. https:\/\/doi.org\/10.1182\/bloodadvances.2023012403","journal-title":"Blood Adv"},{"issue":"1","key":"2627_CR25","doi-asserted-by":"publisher","first-page":"8630","DOI":"10.1038\/s41598-024-59320-z","volume":"14","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang X, Chen H, Zeng H, Wu J, Wang Y et al (2024) Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial. Sci Rep 14(1):8630. https:\/\/doi.org\/10.1038\/s41598-024-59320-z","journal-title":"Sci Rep"},{"issue":"5","key":"2627_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40291-025-00795-5","volume":"29","author":"MD Milosevic","year":"2025","unstructured":"Milosevic MD, Skakic A, Kecman B, Stankovic S, Kovacevic I, Pavlovic S et al (2025) Clinical and genetic profile of 35 patients with glycogen storage disease type 1b: a comparative analysis before and during SGLT2 inhibitor therapy. Mol Diagn Ther 29(5):655\u2013673. https:\/\/doi.org\/10.1007\/s40291-025-00795-5","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"2627_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.7499\/j.issn.1008-8830.2411030","volume":"27","author":"DX Liang","year":"2025","unstructured":"Liang DX, Wu HT, Yang J, Yang M (2025) Efficacy and safety of empagliflozin in the treatment of glycogen storage disease-associated inflammatory bowel disease. Zhongguo Dang Dai Er Ke Za Zhi 27(8):929\u2013935. https:\/\/doi.org\/10.7499\/j.issn.1008-8830.2411030","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"2627_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-905","volume":"14","author":"B Li","year":"2014","unstructured":"Li B, Zhang XZ, Yin AH, Zhao QG, Wu L, Ma YZ et al (2014) High prevalence of thalassemia in migrant populations in Guangdong Province, China. BMC Public Health 14:905. https:\/\/doi.org\/10.1186\/1471-2458-14-905","journal-title":"BMC Public Health"},{"issue":"7","key":"2627_CR29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/dom.14684","volume":"24","author":"K Khunti","year":"2022","unstructured":"Khunti K, Jabbour S, Cos X, Mudaliar S, Mende C, Bonaca M et al (2022) Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: barriers and solutions for improving uptake in routine clinical practice. Diabetes Obes Metab 24(7):1187\u20131196. https:\/\/doi.org\/10.1111\/dom.14684","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2627_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108144","volume":"141","author":"SC Gr\u00fcnert","year":"2024","unstructured":"Gr\u00fcnert SC, Derks TGJ, Mundy H, Dalton RN, Donadieu J, Hofbauer P et al (2024) Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: consensus from an international workshop. Mol Genet Metab 141(3):108144. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108144","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2627_CR31","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10545-015-9864-2","volume":"38","author":"M Hochuli","year":"2015","unstructured":"Hochuli M, Christ E, Meienberg F, Lehmann R, Kr\u00fctzfeldt J, Baumgartner MR (2015) Alternative nighttime nutrition regimens in glycogen storage disease type I: a controlled crossover study. J Inherit Metab Dis 38(6):1093\u20131098. https:\/\/doi.org\/10.1007\/s10545-015-9864-2","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2627_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/moh.0000000000000474","volume":"26","author":"DC Dale","year":"2019","unstructured":"Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E et al (2019) Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol 26(1):16\u201321. https:\/\/doi.org\/10.1097\/moh.0000000000000474","journal-title":"Curr Opin Hematol"},{"issue":"16","key":"2627_CR33","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.12998\/wjcc.v9.i16.4081","volume":"9","author":"FC Lui","year":"2021","unstructured":"Lui FC, Lo OS (2021) Rare complication of inflammatory bowel disease-like colitis from glycogen storage disease type 1b and its surgical management: a case report. World J Clin Cases 9(16):4081\u20134089. https:\/\/doi.org\/10.12998\/wjcc.v9.i16.4081","journal-title":"World J Clin Cases"},{"key":"2627_CR34","doi-asserted-by":"publisher","unstructured":"Zhang MY, Liu YJ, Zhu L (2024) Adverse reaction analysis of mesalazine in the treatment of inflammatory bowel disease. Chin J New Drugs 33(15):1628\u20131632. https:\/\/doi.org\/10.3969\/j.issn.1003-3734.2024.15.015","DOI":"10.3969\/j.issn.1003-3734.2024.15.015"},{"issue":"1","key":"2627_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/08880018.2018.1440675","volume":"35","author":"AM Li","year":"2018","unstructured":"Li AM, Thyagu S, Maze D, Schreiber R, Sirrs S, Stockler-Ipsiroglu S et al (2018) Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. Pediatr Hematol Oncol 35(1):45\u201351. https:\/\/doi.org\/10.1080\/08880018.2018.1440675","journal-title":"Pediatr Hematol Oncol"},{"issue":"9","key":"2627_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood.2019004465","volume":"136","author":"SB Wortmann","year":"2020","unstructured":"Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A et al (2020) Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood 136(9):1033\u20131043. https:\/\/doi.org\/10.1182\/blood.2019004465","journal-title":"Blood"},{"key":"2627_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1365700","volume":"15","author":"A Klinc","year":"2024","unstructured":"Klinc A, Groselj U, Mlinaric M, Homan M, Markelj G, Mezek Novak A et al (2024) Case report: the success of empagliflozin therapy for glycogen storage disease type 1b. Front Endocrinol (Lausanne) 15:1365700. https:\/\/doi.org\/10.3389\/fendo.2024.1365700","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2627_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13023-020-01503-8","volume":"15","author":"SC Gr\u00fcnert","year":"2020","unstructured":"Gr\u00fcnert SC, Elling R, Maag B, Wortmann SB, Derks TGJ, Hannibal L et al (2020) Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. Orphanet J Rare Dis 15(1):218. https:\/\/doi.org\/10.1186\/s13023-020-01503-8","journal-title":"Orphanet J Rare Dis"},{"key":"2627_CR39","doi-asserted-by":"publisher","DOI":"10.37184\/lnjpc.2707-3521.5.28","author":"MNA Khan","year":"2023","unstructured":"Khan MNA, Jabeen S (2023) SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis. Liaquat Nat J Primary Care. https:\/\/doi.org\/10.37184\/lnjpc.2707-3521.5.28","journal-title":"Liaquat Nat J Primary Care"},{"issue":"3","key":"2627_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107712","volume":"140","author":"JP Dewulf","year":"2023","unstructured":"Dewulf JP, Chevalier N, Marie S, Veiga-da-Cunha M (2023) DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia. Mol Genet Metab 140(3):107712. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107712","journal-title":"Mol Genet Metab"},{"key":"2627_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1145111","volume":"14","author":"A Maiorana","year":"2023","unstructured":"Maiorana A, Tagliaferri F, Dionisi-Vici C (2023) Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. Front Endocrinol (Lausanne) 14:1145111. https:\/\/doi.org\/10.3389\/fendo.2023.1145111","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"720","key":"2627_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn4214","volume":"15","author":"F Trepiccione","year":"2023","unstructured":"Trepiccione F, Iervolino A, D\u2019Acierno M, Siccardi S, Costanzo V, Sardella D et al (2023) The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI. Sci Transl Med 15(720):eabn4214. https:\/\/doi.org\/10.1126\/scitranslmed.abn4214","journal-title":"Sci Transl Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02627-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02627-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:39:58Z","timestamp":1776649198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02627-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2627"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02627-8","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}